REFERENCES
1. Ribeiro RC, Antillon F, Pedrosa
F, Pui CH. Global Pediatric Oncology: Lessons From Partnerships Between
High-Income Countries and Low- to Mid-Income Countries. J Clin Oncol.
Jan 1 2016;34(1):53-61. doi:10.1200/JCO.2015.61.9148
2. Rodriguez-Galindo C, Friedrich P, Alcasabas P, et al. Toward the Cure
of All Children With Cancer Through Collaborative Efforts: Pediatric
Oncology As a Global Challenge. J Clin Oncol. Sep 20
2015;33(27):3065-73. doi:10.1200/JCO.2014.60.6376
3. O’Leary M, Krailo M, Anderson JR, Reaman GH, Children’s Oncology G.
Progress in childhood cancer: 50 years of research collaboration, a
report from the Children’s Oncology Group. Semin Oncol. Oct
2008;35(5):484-93. doi:10.1053/j.seminoncol.2008.07.008
4. Barr RD, Antillon Klussmann F, Baez F, et al. Asociacion de
Hemato-Oncologia Pediatrica de Centro America (AHOPCA): a model for
sustainable development in pediatric oncology. Pediatr Blood Cancer. Feb
2014;61(2):345-54. doi:10.1002/pbc.24802
5. Abboud MR, Ghanem K, Muwakkit S. Acute lymphoblastic leukemia in low
and middle-income countries: disease characteristics and treatment
results. Curr Opin Oncol. Nov 2014;26(6):650-5.
doi:10.1097/CCO.0000000000000125
6. Howard SC, Pedrosa M, Lins M, et al. Establishment of a Pediatric
Oncology Program and Outcomes of Childhood Acute Lymphoblastic Leukemia
in a Resource-Poor Area. JAMA. 2004;291(20):2471-2475.
doi:10.1001/jama.291.20.2471
7. Baskin JL, Lezcano E, Kim BS, et al. Management of children with
brain tumors in Paraguay. Neuro Oncol. Feb 2013;15(2):235-41.
doi:10.1093/neuonc/nos291
8. Gajjar A, Finlay JL. The management of children and adolescents with
medulloblastoma in low and middle income countries. Pediatr Blood
Cancer. Apr 2015;62(4):549-50. doi:10.1002/pbc.25371
9. Qaddoumi I, Musharbash A, Elayyan M, et al. Closing the survival gap:
implementation of medulloblastoma protocols in a low-income country
through a twinning program. Int J Cancer. Mar 15 2008;122(6):1203-6.
doi:10.1002/ijc.23160
10. Rajagopal R A-GS, Ganesan D, et al. Challenges of Treating Childhood
Medulloblastoma in a Country With Limited Resources: 20 Years of
Experience at a Single Tertiary Center in Malaysia. J Glob Oncol. Jun 15
2016 3(2):143-156. doi:10.1200/JGO.2015.002659
11. Gibson P, Tong Y, Robinson G, et al. Subtypes of medulloblastoma
have distinct developmental origins. Nature. Dec 23
2010;468(7327):1095-9. doi:10.1038/nature09587
12. Roussel MF, Hatten ME. Cerebellum: Development and Medulloblastoma.
Curr Top Dev Biol. 2011:94: 235-282.
13. Martin AM, Raabe E, Eberhart C, Cohen KJ. Management of pediatric
and adult patients with medulloblastoma. Curr Treat Options Oncol. Dec
2014;15(4):581-94. doi:10.1007/s11864-014-0306-4
14. Srinivasan VM, Ghali MG, North RY, Boghani Z, Hansen D, Lam S.
Modern management of medulloblastoma: Molecular classification,
outcomes, and the role of surgery. Surg Neurol Int. 2016;7(Suppl
44):S1135-S1141. doi:10.4103/2152-7806.196922
15. Evans AE JR, Sposto R, et al. The treatment of medulloblastoma.
Results of a prospective randomized trial of radiation therapy with and
without CCNU, vincristine, and prednisone. J Neurosurg Pediatr. Apr
1990;72(4):572-82. doi:10.3171/jns.1990.72.4.0572
16. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted
craniospinal radiotherapy followed by high-dose chemotherapy and
stem-cell rescue in children with newly diagnosed medulloblastoma (St
Jude Medulloblastoma-96): long-term results from a prospective,
multicentre trial. The Lancet Oncology. 2006;7(10):813-820.
doi:10.1016/s1470-2045(06)70867-1
17. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of
craniospinal radiation therapy followed by adjuvant chemotherapy for
newly diagnosed average-risk medulloblastoma. J Clin Oncol. Sep 1
2006;24(25):4202-8. doi:10.1200/JCO.2006.06.4980
18. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with
medulloblastoma treated with radiation and cisplatin, CCNU, and
vincristine chemotherapy. J Neurosurg Pediatr. Nov 1994;81(5):690-8.
doi:10.3171/jns.1994.81.5.0690.
19. Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic
factors of early childhood medulloblastoma: an international
meta-analysis. J Clin Oncol. Nov 20 2010;28(33):4961-8.
doi:10.1200/JCO.2010.30.2299
20. Zeltzer PM, Boyett, J. M., Finlay, J. L., et al. Metastasis stage,
adjuvant treatment, and residual tumor are prognostic factors for
medulloblastoma in children: conclusions from the Children’s Cancer
Group 921 randomized phase III study. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology, .
1999;17(3):832–845. doi:https://doi.org/10.1200/JCO.1999.17.3.832
21. Ezzat S, Kamal M, El-Khateeb N, et al. Pediatric brain tumors in a
low/middle income country: does it differ from that in developed world?
J Neurooncol. Jan 2016;126(2):371-6. doi:10.1007/s11060-015-1979-7
22. Albright AL, Wisoff JH, Zeltzer PM, Boyett JM, Rorke LB, Stanley P.
Effects of medulloblastoma resections on outcome in children: a report
from the Children’s Cancer Group. Neurosurgery. February 1996;38(2):
:265-71. doi: 10.1097/00006123-199602000-00007
23. Bailey CC, Gnekow A, Wellek S,et al. Prospective randomised trial of
chemotherapy given before radiotherapy in childhood medulloblastoma.
International Society of Paediatric Oncology (SIOP) and the (German)
Society of Paediatric Oncology (GPO): SIOP II. . Med Pediatr Oncol.
September 1995;25(3):166-78. doi:10.1002/mpo.2950250303
24. Albright AL, Sposto R, Holmes E, et al. Correlation of neurosurgical
subspecialization with outcomes in children with malignant brain tumors.
Neurosurgery. October 2000;47(4):879-85.
doi:10.1097/00006123-200010000-00018
25. Thompson EM, Hielscher T, Bouffet E, et al. Prognostic value of
medulloblastoma extent of resection after accounting for molecular
subgroup: a retrospective integrated clinical and molecular analysis.
The Lancet Oncology. 2016;17(4):484-495.
doi:10.1016/s1470-2045(15)00581-1
26. Fuller A, Tran T, Muhumuza M, Haglund MM. Building neurosurgical
capacity in low and middle income countries. eNeurologicalSci. Jun
2016;3:1-6. doi:10.1016/j.ensci.2015.10.003
27. Power-Hays A, Friedrich P, Fernandez G, et al. Delivery of radiation
therapy in resource-limited settings: A pilot quality assessment study.
Pediatr Blood Cancer. Aug 2017;64(8)doi:10.1002/pbc.26480
28. Kortmann RD, Kühl J, Timmermann B, et al,. Postoperative neoadjuvant
chemotherapy before radiotherapy as compared to immediate radiotherapy
followed by maintenance chemotherapy in the treatment of medulloblastoma
in childhood: results of the German prospective randomized trial HIT
’91. Int J Radiat Oncol Biol Phys. Jan 15 2000;46(2):269-79.
doi:10.1016/s0360-3016(99)00369-7.
29. Parkes J, Hendricks M, Ssenyonga P, et al. SIOP PODC adapted
treatment recommendations for standard-risk medulloblastoma in low and
middle income settings. Pediatr Blood Cancer. Apr 2015;62(4):553-64.
doi:10.1002/pbc.25313
30. Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of
childhood medulloblastoma in the molecular era: the current consensus.
Acta Neuropathol. Jun 2016;131(6):821-31. doi:10.1007/s00401-016-1569-6
31. Hwang EI, Kool, M., Burger, P. C., et al. Extensive Molecular and
Clinical Heterogeneity in Patients With Histologically Diagnosed
CNS-PNET Treated as a Single Entity: A Report From the Children’s
Oncology Group Randomized ACNS0332 Trial. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology,.
2018;doi:10.1200/JCO.2017.76.4720
32. Abu Arja MH, Stanek JR, Morales La Madrid AE, et al. The Latin
American Brain Tumor Board teleconference: results of a web-based survey
to evaluate participant experience utilizing this resource. Childs Nerv
Syst. Feb 2019;35(2):257-265. doi:10.1007/s00381-018-4000-x
FIGURE 1 : Geographical assessment of patient location in Peru
by City.
FIGURE 2 : Kaplan Meier curves for this study. A) OS and EFS for
all patients. B) EFS based on treatment period. C) EFS based on
histology. D) EFS based on Metastasis at diagnosis.
TABLE 1 Resources for Pediatric Neuro Oncology
TABLE 2 Demographics and patient characteristics
TABLE 3 Clinical management and pathology
TABLE 4 Factors affecting overall and event-free survival
SUPPLEMENTAL TABLE 1 : Availability of Immunohistochemistry for
the two periods of treatment.
SUPPLEMENTAL FIGURE 1 : Causes of childhood mortality for ages
1-9 were extracted from PAHO database for the years of 1999 and 2015.
Causes are identified by their current ICD 10 code and presented as
number of deaths per 100,000.